Brand Name
Lerochol
Generic Name
Lerodalcibep-Liga
View Brand Information FDA approval date: December 15, 2025
Form: Injection
What is Lerochol (Lerodalcibep-Liga)?
LEROCHOL TM is indicated as an adjunct to diet and exercise to reduce low-density lipoprotein cholesterol in adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia . LEROCHOL is a proprotein convertase subtilisin kexin type 9 inhibitor indicated as an adjunct to diet and exercise: to reduce low-density lipoprotein cholesterol in adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia .
Approved To Treat
Top Global Experts
Save this treatment for later
Not sure about your diagnosis?
Related Clinical Trials
There is no clinical trials being done for this treatment